Systematic review: Vitamin D and cardiometabolic outcomes.
Systematic review: Vitamin D and cardiometabolic outcomes.
复制标题
系统评价：维生素D和心脏代谢结果。
DOI：
10.7326/0003-4819-152-5-201003020-00009
复制
发表时间：
2010-03-02
影响因子：
39.2
通讯作者：
Balk EM
中科院分区：
文献类型：
--
作者：
Pittas AG;Chung M;Trikalinos T;Mitri J;Brendel M;Patel K;Lichtenstein AH;Lau J;Balk EM
维生素D可能会改变心脏代谢结果（2型糖尿病，高血压或心血管疾病）的风险。研究维生素D状态与维生素D补充剂对一般健康成人心脏代谢结果的影响之间的关系。MEDLINE（开始至2009年11月4日）和科克伦临床试验注册（2009年第4季度）中的英语研究。11位评论者筛选引文，以确定报告维生素D状态与心脏代谢结果相关的纵向队列研究和维生素D补充剂的随机试验。五名独立的评审员提取了有关研究进行，参与者特征，结果和质量的数据。分歧通过协商一致得到解决。13项观察性研究（14个队列）和18项试验符合条件。6项分析中的3项（来自4个不同的队列）报告了维生素D水平最高组与最低组的糖尿病发病风险较低。七项试验发现，维生素D补充剂对糖尿病或偶发糖尿病没有影响。通过对3个队列的荟萃分析，较低的25-羟基维生素D浓度与高血压事件相关（相对风险1.8; 95%置信区间[CI] 1.3，2.4）。通过对10项试验的荟萃分析，补充剂无显著降低收缩压（加权平均差[WMD]-1.9; 95% CI-4.2，0.4 mm Hg），不影响舒张压（WMD-0.1; 95% CI-0.7，0.5 mm Hg）。在7项分析中的5项（6个队列）中，较低的25-羟基维生素D浓度与心血管疾病事件相关。四项试验发现补充剂对心血管结局没有影响。研究对象主要是白人。观察性研究是异质性的。几项试验报告了事后分析。维生素D状态和心脏代谢结果之间的关联尚不确定。试验表明，在给定剂量下补充维生素D没有临床显著效果。
Vitamin D may modify risk of cardiometabolic outcomes (type 2 diabetes, hypertension, or cardiovascular disease). Examine the association of vitamin D status and the effect of vitamin D supplementation on cardiometabolic outcomes in generally healthy adults. English-language studies in MEDLINE (inception to 4 November 2009) and the Cochrane Clinical Trials Register (4th quarter of 2009). Eleven reviewers screened citations to identify longitudinal cohort studies reporting associations of vitamin D status and randomized trials of vitamin D supplementation on cardiometabolic outcomes. Five independent reviewers extracted data about study conduct, participant characteristics, outcomes, and quality. Differences were resolved by consensus. Thirteen observational studies (14 cohorts) and 18 trials were eligible. Three of 6 analyses (from 4 different cohorts) reported a lower incident diabetes risk in highest versus lowest vitamin D status groups. Seven trials found no effect of vitamin D supplementation on glycemia or incident diabetes. By meta-analysis of 3 cohorts, lower 25-hydroxyvitamin D concentration was associated with incident hypertension (relative risk 1.8; 95% confidence interval [CI] 1.3, 2.4). By meta-analyses of 10 trials, supplementation nonsignificantly reduced systolic blood pressure (weighted mean difference [WMD] −1.9; 95% CI −4.2, 0.4 mm Hg) and did not affect diastolic blood pressure (WMD −0.1; 95% CI −0.7, 0.5 mm Hg). Lower 25-hydroxyvitamin D concentration was associated with incident cardiovascular disease in 5 of 7 analyses (6 cohorts). Four trials found no effect of supplementation on cardiovascular outcomes. Studies included primarily whites. Observational studies were heterogeneous. Several trials reported post hoc analyses. An association between vitamin D status and cardiometabolic outcomes is uncertain. Trials showed no clinically significant effect of vitamin D supplementation at doses given.
登录
查看更多内容
影响因子：
5.4
作者：
Knekt, Paul;Laaksonen, Maarit;Reunanen, Antti
通讯作者：
Reunanen, Antti
影响因子：
7.3
作者：
Borges, ACR;Feres, T;Paiva, TB
通讯作者：
Paiva, TB
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
8.3
作者：
MACCARTHY, EP;YAMASHITA, W;OOI, BS
通讯作者：
OOI, BS
影响因子：
16.2
作者：
de Boer, Ian H.;Tinker, Lesley F.;Weiss, Noel S.
通讯作者：
Weiss, Noel S.